6 or 3 months of anticoagulant therapy did not differ for treatment failure in patients with DVT, PE, or both: COMMENTARY

Kamphuisen, Pieter W.
September 2007
ACP Journal Club;Sept/Oct2007, Vol. 147 Issue 2, p37
Academic Journal
The article reports that duration of six or three months of anticoagulant therapy that did not differ for treatment failure in patients with Deep Venous Thrombosis (DVT) , Pulmonary Embolism (PE), or both. It reports on prevention of repetitive Venous ThromboEmbolism (VTE) by using the vitamin K antagonists. It mentions recurrent VTE in about 10% of patients after ceasing anticoagulant therapy. Three or six months of the therapy in the patients are compared. Several shortcomings are also given.


Related Articles

  • 6 or 3 months of anticoagulant therapy did not differ for treatment failure in patients with DVT, PE, or both.  // ACP Journal Club;Sept/Oct2007, Vol. 147 Issue 2, p37 

    The article reports on a study concerned with duration of oral anticoagulant therapy in patients having Deep Venous Thrombosis (DVT), Pulmonary Embolism (PE), or both. The method involved a randomized controlled trial (RCT) with follow-up period of one year. Details regarding exclusion,...

  • A Case of Pulmonary Embolism on Dabigatran. Tandon, Pragati; Khanijo, Sameer // Journal of Medical Cases;2013, Vol. 4 Issue 8, p550 

    It is well known that hospitalized medical patients are at higher risk for the development of venous thromboembolism. As a result patients are placed on standard prophylactic anticoagulation. As newer anticoagulants are coming to the market patients on these novel oral agents are continued on...

  • New oral anticoagulants for preventing venous thromboembolism. Haut, Elliott R.; Lau, Brandyn D.; Streiff, Michael B. // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;6/30/2012, Vol. 344 Issue 7863, p10 

    No abstract available.

  • WOEST: Less bleeding risk with dual therapy.  // Cardiology Today;Oct2012, Vol. 15 Issue 10, p16 

    The article focuses on a study which revealed that the addition of clopidogrel only to oral anticoagulants and the omission of aspirin resulted to less bleeding and appears to be safe in preventing thrombotic and thromboembolic complications for patients on oral anticoagulants undergoing...

  • Bleeding Risk Scores Identified Patients With DVT or PE at Low Risk of Bleeding. Mosley, Mary; Kline, Jeffrey A. // MD Conference Express;Oct2015, Vol. 15 Issue 28, p22 

    A secondary analysis of pooled data from the EINSTEIN-DVT and EINSTEIN-PE studies demonstrated the utility of 4 different bleeding risk scores to identify patients with deep vein thrombosis or pulmonary embolism who are at a low risk of bleeding. Patients aged < 65 years and without a...

  • Save costs with DOACs for VTE prevention in Spain.  // PharmacoEconomics & Outcomes News;Jun2014, Vol. 705 Issue 1, p10 

    The article reports on a 2014 study in Spain showing the cost saving alternatives of direct oral anticoagulants (DOACs) for enoxaparin in preventing venous thromboembolism (VTE) after total hip replacement (THR) or total knee replacement (TKR).

  • Prevention and Clinical Outcomes in Older Inpatients with Suspected Venous Thromboembolism. Lee, Jung-Ah; Zierler, Brenda K. // Journal of Gerontological Nursing;Apr2010, Vol. 36 Issue 4, p40 

    Venous thromboembolism (VTE) is one of the most common preventable disorders among hospital inpatients. Advancing age is a major risk factor for VTE. The purpose of this study was to describe and compare prevention practices and clinical outcomes in older (age 65 and older) versus younger (ages...

  • Fatal pulmonary embolism following spinal surgery in a patient with permanent inferior vena cava filter placement. Takai, Noriko; Takasugi, Yoshihiro; Kajikawa, Ryuji; Takase, Toru; Yamamoto, Yoshio; Nakao, Shinichi // Journal of Anesthesia;Aug2014, Vol. 28 Issue 4, p606 

    It has been proven that the use of an inferior vena cava filter (IVCF) is effective in decreasing the incidence of pulmonary embolism (PE) in high-risk spinal surgery patients. A case of fatal PE after spinal surgery in a 78-year-old woman who had a history of pulmonary hypertension due to...

  • A Paradigm Shift in Anticoagulation? Kaddis, Atheer A. // American Health & Drug Benefits;Mar/Apr2012, Vol. 5 Issue 2, p122 

    In this article the author discusses the efficacy and cost effectiveness of innovative anticoagulants such as rivaroxaban, apixaban, and dabigatran and the article "Benefits of Novel Oral Anticoagulant Agents for Thromboprophylaxis After Total Hip or Knee Arthroplasty" by Richard J. Friedman. He...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics